Altering The Treatment Paradigm for Obesity and MACE Indications with Oral GLP-1's
September 24th 2025Madeline Verbeke, Senior Clinical Advisor, MMIT, touches on changing the treatment paradigm for obesity & MACE indications, important considerations for translating cardiovascular benefits in injectable GLP-1s, and clinical potential for oral GLP-1s.
Injectable and Oral GLP-1's Impact on The Clinical Landscape
September 23rd 2025Madeline Verbeke, Senior Clinical Advisor, MMIT, touches on injectable and oral GLP-1's impact on the clinical landscape, and the clinical and scientific hurdles oral GLP-1 formulations need to overcome to gain comparable traction.
Influence of Pharmacologic Options on Clinical Practices
September 12th 2025Helen Sabzevari, PhD, president and CEO of Precigen, explains how Papzimeos transforms clinical practice by establishing the first FDA-approved standard of care for recurrent respiratory papillomatosis (RRP), shifting treatment from repeated surgeries to an immunotherapy that addresses the root HPV infection, with future plans to expand into pediatric populations and redosing strategies.
Setting Precedents for Rare Disease Therapies
September 11th 2025Helen Sabzevari, PhD, president and CEO of Precigen, reflects on how Papzimeos sets an important precedent for rare disease therapies, with its broad FDA label for all adult patients with recurrent respiratory papillomatosis (RRP) highlighting the potential for earlier intervention to prevent irreversible damage and establish new standards of care.
Characterizing Disscussions with Regulators Around Clinical Data
September 10th 2025Helen Sabzevari, PhD, president and CEO of Precigen, discusses the FDA’s decision to grant full approval to Papzimeos without requiring a confirmatory trial, highlighting how strong safety, efficacy, and durability data supported a broad label for all adult patients with recurrent respiratory papillomatosis (RRP).
Key Factors in Papzimeos' FDA Approval in Adults Patients with Recurrent Respiratory Papillomatosis
September 9th 2025Helen Sabzevari, PhD, president and CEO of Precigen, explains how Papzimeos, developed using the company’s AdenoVerse platform, became the first FDA-approved therapy for adult patients with recurrent respiratory papillomatosi.
Recurrent Respiratory Papillomatosis Treatments Before Papzimeos
September 9th 2025In this video interview, Helen Sabzevari, PhD, president and CEO of Precigen, discusses the background of Recurrent Respiratory Papillomatosis treatments that led to Papzimeos becoming the first FDA-approved therapy for Recurrent Respiratory Papillomatosis.
Pharmaceutical Executive Daily: September 8, 2025
September 8th 2025In today’s Pharmaceutical Executive Daily, we review the wave of pharmaceutical layoffs shaping 2025, highlight the latest Pharm Exec Top 50 company rankings, and cover BioNTech and Duality Biologics’ clinical trial success with BNT323.
How Doceree is Leveraging its Point-of-Care Marketing
August 29th 2025Doctor Harshit Jain, Founder and Global CEO of Doceree, spoke with Pharmaceutical Executive about leveraging point-of-care marketing momentum and its influence on decision making and how does Doceree maintain contextual relevance in marketing on a national scale.